"The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and "...
(Generic versions may still be available.)
Coadministration of AGENERASE is contraindicated with drugs that are highly dependent on CYP3A4 for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These drugs are listed in Table 6.
Table 6. Drugs That Are Contraindicated With AGENERASE
|Drug Class||Drugs Within Class That Are CONTRAINDICATED with AGENERASE|
|Ergot derivatives||Dihydroergotamine, ergonovine, ergotamine, methylergonovine|
|GI motility agent||Cisapride|
If AGENERASE is coadministered with ritonavir, the antiarrhythmic agents flecainide and propafenone are also contraindicated.
Because of the potential toxicity from the large amount of the excipient, propylene glycol, contained in AGENERASE Oral Solution, that formulation is contraindicated in certain patient populations and should be used with caution in others. Consult the complete prescribing information for AGENERASE Oral Solution for full information.
AGENERASE is contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of this product.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 7/16/2008
Additional Agenerase Capsules Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.